Cancel anytime
Novanta Inc (NOVT)NOVT
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: NOVT (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -23.05% | Upturn Advisory Performance 3 | Avg. Invested days: 42 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -23.05% | Avg. Invested days: 42 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.95B USD |
Price to earnings Ratio 99.83 | 1Y Target Price 178 |
Dividends yield (FY) - | Basic EPS (TTM) 1.66 |
Volume (30-day avg) 171188 | Beta 1.29 |
52 Weeks Range 142.35 - 187.12 | Updated Date 11/20/2024 |
Company Size Mid-Cap Stock | Market Capitalization 5.95B USD | Price to earnings Ratio 99.83 | 1Y Target Price 178 |
Dividends yield (FY) - | Basic EPS (TTM) 1.66 | Volume (30-day avg) 171188 | Beta 1.29 |
52 Weeks Range 142.35 - 187.12 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-11-05 | When BeforeMarket |
Estimate 0.85 | Actual 0.85 |
Report Date 2024-11-05 | When BeforeMarket | Estimate 0.85 | Actual 0.85 |
Profitability
Profit Margin 6.52% | Operating Margin (TTM) 14.34% |
Management Effectiveness
Return on Assets (TTM) 5.35% | Return on Equity (TTM) 8.67% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE 99.83 | Forward PE - |
Enterprise Value 6374481476 | Price to Sales(TTM) 6.45 |
Enterprise Value to Revenue 6.91 | Enterprise Value to EBITDA 37.44 |
Shares Outstanding 35921300 | Shares Floating 35583308 |
Percent Insiders 0.87 | Percent Institutions 103.89 |
Trailing PE 99.83 | Forward PE - | Enterprise Value 6374481476 | Price to Sales(TTM) 6.45 |
Enterprise Value to Revenue 6.91 | Enterprise Value to EBITDA 37.44 | Shares Outstanding 35921300 | Shares Floating 35583308 |
Percent Insiders 0.87 | Percent Institutions 103.89 |
Analyst Ratings
Rating 4 | Target Price 165.5 | Buy 1 |
Strong Buy 1 | Hold 1 | Sell - |
Strong Sell - |
Rating 4 | Target Price 165.5 | Buy 1 | Strong Buy 1 |
Hold 1 | Sell - | Strong Sell - |
AI Summarization
Novanta Inc. Overview:
Company Profile
History: Novanta, formerly known as Acterna, was incorporated in Delaware in 1984. The company initially focused on telecom test equipment but diversified into photonics, vision, and precision motion technologies through acquisitions and organic growth. In 2015, the company rebranded as Novanta.
Core Business Areas:
- Photonics: Novanta designs and manufactures laser-based solutions for medical, industrial, and defense applications.
- Vision & Precision Motion: This segment provides vision inspection systems and precision motion control solutions for the electronics, medical, and industrial automation markets.
Leadership & Structure:
- CEO: Matthieu Verwaerde
- President: Matthieu Verwaerde
- CFO: Alain Monié
- The company follows a decentralized organizational structure with separate business units for its core segments.
Top Products & Market Share:
- Photonics: VCSELs (Vertical-cavity surface-emitting lasers), laser modules, and fiber-optic components
- Vision & Precision Motion: Machine vision systems, precision motion stages, and linear motor controllers
- Market Share: Novanta holds a leading position in the VCSEL market and a significant share in the vision and precision motion segments. However, market share data varies across specific product categories and applications.
Total Addressable Market:
- Photonics: Estimated at $5.9 billion (2022) and projected to grow at a CAGR of 7.4% (2022-2027).
- Vision & Precision Motion: Estimated at $15.8 billion (2022) and projected to grow at a CAGR of 6.4% (2022-2027).
Financial Performance:
- Revenue: $545.8 million (2022)
- Net Income: $38.8 million (2022)
- Profit Margin: 7.1% (2022)
- EPS: $1.45 (2022)
- Year-over-Year: Revenue grew 5.7% year-over-year in 2022. Net income and profit margin have seen fluctuations in recent years.
- Cash Flow: The company has a healthy cash flow position with $51.8 million in operating cash flow in 2022.
- Balance Sheet: Novanta has a moderate debt level and a healthy current ratio, indicating strong financial position.
Dividends & Shareholder Returns:
- Dividend History: Novanta has a consistent dividend payment history with a current dividend yield of 0.6%. However, the company does not have a long dividend growth history.
- Shareholder Returns: Total shareholder return (TSR) over the past year was -23.4%, underperforming the S&P 500. However, long-term TSR was positive over 5 and 10 years.
Growth Trajectory:
- Historical Growth: Revenue grew at a CAGR of 8.5% over the past 5 years.
- Future Growth: Novanta expects moderate organic growth in the coming years, driven by increasing demand for its products in target markets.
- Product Launches & Initiatives: The company is focusing on new product launches, particularly in the medical and industrial automation sectors, to drive future growth.
Market Dynamics:
- Industry Trends: Increasing demand for laser-based solutions, miniaturization of electronics, and automation trends are driving growth in Novanta's target markets.
- Competitive Landscape: The company faces competition from established players and new entrants in its target markets. However, Novanta's technology leadership and customer relationships provide competitive advantages.
Competitors:
- Photonics: II-VI Incorporated (IIVI), Lumentum Holdings (LITE), and ams-OSRAM (AMS)
- Vision & Precision Motion: Cognex Corporation (CGNX), Omron Corporation (OMRN), and Keyence Corporation (KEY)
Challenges & Opportunities:
- Challenges: Supply chain disruptions, rising raw material costs, and competitive pressures are key challenges.
- Opportunities: Growing demand in medical and industrial markets, new product development, and strategic acquisitions present significant opportunities.
Recent Acquisitions:
- 2023: Novanta acquired Excelitas' Photonics and Sensing businesses, expanding its portfolio into sensing, detection, and illumination technologies.
AI-Based Fundamental Rating:
- Rating: 8/10
- Justification: Novanta possesses strong financial health, a leading market position in core segments, and promising growth prospects. However, the company's moderate past and future growth rate and lack of dividend growth limit the rating.
Sources & Disclaimer:
- Company website: https://www.novanta.com/
- SEC filings: https://www.sec.gov/edgar/searchedgar/companysearch.html
- Yahoo Finance: https://finance.yahoo.com/quote/NOVT/
- Market research reports from reputable sources
- This report is provided for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novanta Inc
Exchange | NASDAQ | Headquaters | Bedford, MA, United States |
IPO Launch date | 2016-01-04 | CEO & Chairman of the Board | Mr. Matthijs Glastra |
Sector | Technology | Website | https://www.novanta.com |
Industry | Scientific & Technical Instruments | Full time employees | 2900 |
Headquaters | Bedford, MA, United States | ||
CEO & Chairman of the Board | Mr. Matthijs Glastra | ||
Website | https://www.novanta.com | ||
Website | https://www.novanta.com | ||
Full time employees | 2900 |
Novanta Inc., together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. The Precision Medicine and Manufacturing segment offers photonics-based solutions, including laser scanning, beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. The Robotics and Automation segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force and distributors under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, General Scanning, ATI Industrial Automation, Celera Motion, IMS, MicroE, Applimotion, Zettlex, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.